 | • レポートコード：D0GIR-02197 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール • 産業分類：New Technology |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、新型コロナウイルス感染症不活化ワクチンの世界市場を広く調査・分析し、今後の市場展望をまとめております。新型コロナウイルス感染症不活化ワクチンの種類別市場規模（臨床試験中、非臨床試験中）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Inovio Pharmaceuticals、Altimmune、Codagenix, Inc.、Takis Biotech (Evvivax)、Janssen Pharmaceutical Companies、Zydus Cadila、CanSino Biologics、Bravovax、GeoVax, Inc.、Vaxart、Generex、Baylor、ExpreS2ion Biotechnologies ApS、Moderna, Inc.、Novavax, Inc.、Vaxil Bio Ltd.、Clover Biopharmaceuticals、iBio, Inc.、Sanofi Pasteur、GSK、Curevac、ImmunoPrecise ・地域別グローバル市場分析 2015年-2020年 ・新型コロナウイルス感染症不活化ワクチンの北米市場（アメリカ、カナダ、メキシコ） ・新型コロナウイルス感染症不活化ワクチンのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・新型コロナウイルス感染症不活化ワクチンのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・新型コロナウイルス感染症不活化ワクチンの南米市場（ブラジル、アルゼンチン） ・新型コロナウイルス感染症不活化ワクチンの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：臨床試験中、非臨床試験中 ・用途別分析：病院、クリニック、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The COVID-19 Inactivated Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global COVID-19 Inactivated Vaccine sales will be xx in 2020 from COVID-19 Inactivated Vaccine million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global COVID-19 Inactivated Vaccine market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the COVID-19 Inactivated Vaccine industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on COVID-19 Inactivated Vaccine and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
COVID-19 Inactivated Vaccine market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, COVID-19 Inactivated Vaccine market has been segmented into:
In Clinical Trials
Out-of-Clinical Trials
By Application, COVID-19 Inactivated Vaccine has been segmented into:
Hospital
Clinic
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global COVID-19 Inactivated Vaccine market presented in the report. This section sheds light on the sales growth of different regional and country-level COVID-19 Inactivated Vaccine markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global COVID-19 Inactivated Vaccine market.
The report offers in-depth assessment of the growth and other aspects of the COVID-19 Inactivated Vaccine market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and COVID-19 Inactivated Vaccine Market Share Analysis
COVID-19 Inactivated Vaccine competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, COVID-19 Inactivated Vaccine sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the COVID-19 Inactivated Vaccine sales, revenue and market share for each player covered in this report.
The major players covered in COVID-19 Inactivated Vaccine are:
Inovio Pharmaceuticals
Altimmune
Codagenix, Inc.
Takis Biotech (Evvivax)
Janssen Pharmaceutical Companies
Zydus Cadila
CanSino Biologics
Bravovax
GeoVax, Inc.
Vaxart
Generex
Baylor
ExpreS2ion Biotechnologies ApS
Moderna, Inc.
Novavax, Inc.
Vaxil Bio Ltd.
Clover Biopharmaceuticals
iBio, Inc.
Sanofi Pasteur
GSK
Curevac
ImmunoPrecise
Among other players domestic and global, COVID-19 Inactivated Vaccine market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 COVID-19 Inactivated Vaccine Market Overview
1.1 Product Overview and Scope of COVID-19 Inactivated Vaccine
1.2 Classification of COVID-19 Inactivated Vaccine by Type
1.2.1 Global COVID-19 Inactivated Vaccine Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global COVID-19 Inactivated Vaccine Revenue Market Share by Type in 2019
1.2.3 In Clinical Trials
1.2.4 Out-of-Clinical Trials
1.3 Global COVID-19 Inactivated Vaccine Market by Application
1.3.1 Overview: Global COVID-19 Inactivated Vaccine Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global COVID-19 Inactivated Vaccine Market by Regions
1.4.1 Global COVID-19 Inactivated Vaccine Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of COVID-19 Inactivated Vaccine (2015-2025)
1.4.3 North America (USA, Canada and Mexico) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: COVID-19 Inactivated Vaccine Industry Impact
1.5.1 COVID-19 Potential Implications for the COVID-19 Inactivated Vaccine
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on COVID-19 Inactivated Vaccine
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Inovio Pharmaceuticals
2.1.1 Inovio Pharmaceuticals Details
2.1.2 Inovio Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Inovio Pharmaceuticals SWOT Analysis
2.1.4 Inovio Pharmaceuticals Product and Services
2.1.5 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.2 Altimmune
2.2.1 Altimmune Details
2.2.2 Altimmune Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Altimmune SWOT Analysis
2.2.4 Altimmune Product and Services
2.2.5 Altimmune COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.3 Codagenix, Inc.
2.3.1 Codagenix, Inc. Details
2.3.2 Codagenix, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Codagenix, Inc. SWOT Analysis
2.3.4 Codagenix, Inc. Product and Services
2.3.5 Codagenix, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.4 Takis Biotech (Evvivax)
2.4.1 Takis Biotech (Evvivax) Details
2.4.2 Takis Biotech (Evvivax) Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Takis Biotech (Evvivax) SWOT Analysis
2.4.4 Takis Biotech (Evvivax) Product and Services
2.4.5 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.5 Janssen Pharmaceutical Companies
2.5.1 Janssen Pharmaceutical Companies Details
2.5.2 Janssen Pharmaceutical Companies Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Janssen Pharmaceutical Companies SWOT Analysis
2.5.4 Janssen Pharmaceutical Companies Product and Services
2.5.5 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.6 Zydus Cadila
2.6.1 Zydus Cadila Details
2.6.2 Zydus Cadila Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Zydus Cadila SWOT Analysis
2.6.4 Zydus Cadila Product and Services
2.6.5 Zydus Cadila COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.7 CanSino Biologics
2.7.1 CanSino Biologics Details
2.7.2 CanSino Biologics Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 CanSino Biologics SWOT Analysis
2.7.4 CanSino Biologics Product and Services
2.7.5 CanSino Biologics COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bravovax
2.8.1 Bravovax Details
2.8.2 Bravovax Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bravovax SWOT Analysis
2.8.4 Bravovax Product and Services
2.8.5 Bravovax COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.9 GeoVax, Inc.
2.9.1 GeoVax, Inc. Details
2.9.2 GeoVax, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 GeoVax, Inc. SWOT Analysis
2.9.4 GeoVax, Inc. Product and Services
2.9.5 GeoVax, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.10 Vaxart
2.10.1 Vaxart Details
2.10.2 Vaxart Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Vaxart SWOT Analysis
2.10.4 Vaxart Product and Services
2.10.5 Vaxart COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.11 Generex
2.11.1 Generex Details
2.11.2 Generex Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Generex SWOT Analysis
2.11.4 Generex Product and Services
2.11.5 Generex COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.12 Baylor
2.12.1 Baylor Details
2.12.2 Baylor Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Baylor SWOT Analysis
2.12.4 Baylor Product and Services
2.12.5 Baylor COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.13 ExpreS2ion Biotechnologies ApS
2.13.1 ExpreS2ion Biotechnologies ApS Details
2.13.2 ExpreS2ion Biotechnologies ApS Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 ExpreS2ion Biotechnologies ApS SWOT Analysis
2.13.4 ExpreS2ion Biotechnologies ApS Product and Services
2.13.5 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.14 Moderna, Inc.
2.14.1 Moderna, Inc. Details
2.14.2 Moderna, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Moderna, Inc. SWOT Analysis
2.14.4 Moderna, Inc. Product and Services
2.14.5 Moderna, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.15 Novavax, Inc.
2.15.1 Novavax, Inc. Details
2.15.2 Novavax, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Novavax, Inc. SWOT Analysis
2.15.4 Novavax, Inc. Product and Services
2.15.5 Novavax, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.16 Vaxil Bio Ltd.
2.16.1 Vaxil Bio Ltd. Details
2.16.2 Vaxil Bio Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Vaxil Bio Ltd. SWOT Analysis
2.16.4 Vaxil Bio Ltd. Product and Services
2.16.5 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.17 Clover Biopharmaceuticals
2.17.1 Clover Biopharmaceuticals Details
2.17.2 Clover Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Clover Biopharmaceuticals SWOT Analysis
2.17.4 Clover Biopharmaceuticals Product and Services
2.17.5 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.18 iBio, Inc.
2.18.1 iBio, Inc. Details
2.18.2 iBio, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 iBio, Inc. SWOT Analysis
2.18.4 iBio, Inc. Product and Services
2.18.3 iBio, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.19 Sanofi Pasteur
2.19.1 Sanofi Pasteur Details
2.19.2 Sanofi Pasteur Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Sanofi Pasteur SWOT Analysis
2.19.4 Sanofi Pasteur Product and Services
2.19.5 Sanofi Pasteur COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.20 GSK
2.20.1 GSK Details
2.20.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 GSK SWOT Analysis
2.20.4 GSK Product and Services
2.20.5 GSK COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.21 Curevac
2.21.1 Curevac Details
2.21.2 Curevac Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Curevac SWOT Analysis
2.21.4 Curevac Product and Services
2.21.5 Curevac COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
2.22 ImmunoPrecise
2.22.1 ImmunoPrecise Details
2.22.2 ImmunoPrecise Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 ImmunoPrecise SWOT Analysis
2.22.4 ImmunoPrecise Product and Services
2.22.5 ImmunoPrecise COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global COVID-19 Inactivated Vaccine Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 COVID-19 Inactivated Vaccine Players Market Share
3.2.2 Top 10 COVID-19 Inactivated Vaccine Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global COVID-19 Inactivated Vaccine Revenue and Market Share by Regions
4.2 North America COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
4.3 Europe COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
4.5 South America COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
5 North America COVID-19 Inactivated Vaccine Revenue by Countries
5.1 North America COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
5.2 USA COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
5.3 Canada COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
5.4 Mexico COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
6 Europe COVID-19 Inactivated Vaccine Revenue by Countries
6.1 Europe COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
6.2 Germany COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
6.3 UK COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
6.4 France COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
6.5 Russia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
6.6 Italy COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
7 Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Countries
7.1 Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
7.2 China COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
7.3 Japan COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
7.4 Korea COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
7.5 India COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
8 South America COVID-19 Inactivated Vaccine Revenue by Countries
8.1 South America COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
8.2 Brazil COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
8.3 Argentina COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue COVID-19 Inactivated Vaccine by Countries
9.1 Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
9.2 Saudi Arabia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
9.3 UAE COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
9.4 Egypt COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
9.5 South Africa COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global COVID-19 Inactivated Vaccine Revenue and Market Share by Type (2015-2020)
10.2 Global COVID-19 Inactivated Vaccine Market Forecast by Type (2019-2024)
10.3 In Clinical Trials Revenue Growth Rate (2015-2025)
10.4 Out-of-Clinical Trials Revenue Growth Rate (2015-2025)
11 Global COVID-19 Inactivated Vaccine Market Segment by Application
11.1 Global COVID-19 Inactivated Vaccine Revenue Market Share by Application (2015-2020)
11.2 COVID-19 Inactivated Vaccine Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
11.5 Other Revenue Growth (2015-2020)
12 Global COVID-19 Inactivated Vaccine Market Size Forecast (2021-2025)
12.1 Global COVID-19 Inactivated Vaccine Market Size Forecast (2021-2025)
12.2 Global COVID-19 Inactivated Vaccine Market Forecast by Regions (2021-2025)
12.3 North America COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
12.4 Europe COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
12.6 South America COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global COVID-19 Inactivated Vaccine Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of COVID-19 Inactivated Vaccine by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global COVID-19 Inactivated Vaccine Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market COVID-19 Inactivated Vaccine Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global COVID-19 Inactivated Vaccine Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Inovio Pharmaceuticals Corporate Information, Location and Competitors
Table 7. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Major Business
Table 8. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 9. Inovio Pharmaceuticals SWOT Analysis
Table 10. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions
Table 11. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Altimmune Corporate Information, Location and Competitors
Table 13. Altimmune COVID-19 Inactivated Vaccine Major Business
Table 14. Altimmune COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2018-2019)
Table 15. Altimmune SWOT Analysis
Table 16. Altimmune COVID-19 Inactivated Vaccine Product and Solutions
Table 17. Altimmune COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Codagenix, Inc. Corporate Information, Location and Competitors
Table 19. Codagenix, Inc. COVID-19 Inactivated Vaccine Major Business
Table 20. Codagenix, Inc. COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 21. Codagenix, Inc. SWOT Analysis
Table 22. Codagenix, Inc. COVID-19 Inactivated Vaccine Product and Solutions
Table 23. Codagenix, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Takis Biotech (Evvivax) Corporate Information, Location and Competitors
Table 25. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Major Business
Table 26. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 27. Takis Biotech (Evvivax) SWOT Analysis
Table 28. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product and Solutions
Table 29. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Janssen Pharmaceutical Companies Corporate Information, Location and Competitors
Table 31. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Major Business
Table 32. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 33. Janssen Pharmaceutical Companies SWOT Analysis
Table 34. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product and Solutions
Table 35. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Zydus Cadila Corporate Information, Location and Competitors
Table 37. Zydus Cadila COVID-19 Inactivated Vaccine Major Business
Table 38. Zydus Cadila COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 39. Zydus Cadila SWOT Analysis
Table 40. Zydus Cadila COVID-19 Inactivated Vaccine Product and Solutions
Table 41. Zydus Cadila COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. CanSino Biologics Corporate Information, Location and Competitors
Table 43. CanSino Biologics COVID-19 Inactivated Vaccine Major Business
Table 44. CanSino Biologics COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 45. CanSino Biologics SWOT Analysis
Table 46. CanSino Biologics COVID-19 Inactivated Vaccine Product and Solutions
Table 47. CanSino Biologics COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Bravovax Corporate Information, Location and Competitors
Table 49. Bravovax COVID-19 Inactivated Vaccine Major Business
Table 50. Bravovax COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 51. Bravovax SWOT Analysis
Table 52. Bravovax COVID-19 Inactivated Vaccine Product and Solutions
Table 53. Bravovax COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. GeoVax, Inc. Corporate Information, Location and Competitors
Table 55. GeoVax, Inc. COVID-19 Inactivated Vaccine Major Business
Table 56. GeoVax, Inc. COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 57. GeoVax, Inc. SWOT Analysis
Table 58. GeoVax, Inc. COVID-19 Inactivated Vaccine Product and Solutions
Table 59. GeoVax, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Vaxart Corporate Information, Location and Competitors
Table 61. Vaxart COVID-19 Inactivated Vaccine Major Business
Table 62. Vaxart COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 63. Vaxart SWOT Analysis
Table 64. Vaxart COVID-19 Inactivated Vaccine Product and Solutions
Table 65. Vaxart COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Generex Corporate Information, Location and Competitors
Table 67. Generex COVID-19 Inactivated Vaccine Major Business
Table 68. Generex COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 69. Generex SWOT Analysis
Table 70. Generex COVID-19 Inactivated Vaccine Product and Solutions
Table 71. Generex COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Baylor Corporate Information, Location and Competitors
Table 73. Baylor COVID-19 Inactivated Vaccine Major Business
Table 74. Baylor COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 75. Baylor SWOT Analysis
Table 76. Baylor COVID-19 Inactivated Vaccine Product and Solutions
Table 77. Baylor COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. ExpreS2ion Biotechnologies ApS Corporate Information, Location and Competitors
Table 79. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Major Business
Table 80. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 81. ExpreS2ion Biotechnologies ApS SWOT Analysis
Table 82. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product and Solutions
Table 83. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 84. Moderna, Inc. Corporate Information, Location and Competitors
Table 85. Moderna, Inc. COVID-19 Inactivated Vaccine Major Business
Table 86. Moderna, Inc. COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 87. Moderna, Inc. SWOT Analysis
Table 88. Moderna, Inc. COVID-19 Inactivated Vaccine Product and Solutions
Table 89. Moderna, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 90. Novavax, Inc. Corporate Information, Location and Competitors
Table 91. Novavax, Inc. COVID-19 Inactivated Vaccine Major Business
Table 92. Novavax, Inc. COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 93. Novavax, Inc. SWOT Analysis
Table 94. Novavax, Inc. COVID-19 Inactivated Vaccine Product and Solutions
Table 95. Novavax, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 96. Vaxil Bio Ltd. Corporate Information, Location and Competitors
Table 97. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Major Business
Table 98. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 99. Vaxil Bio Ltd. SWOT Analysis
Table 100. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product and Solutions
Table 101. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 102. Clover Biopharmaceuticals Corporate Information, Location and Competitors
Table 103. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Major Business
Table 104. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 105. Clover Biopharmaceuticals SWOT Analysis
Table 106. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions
Table 107. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 108. iBio, Inc. COVID-19 Inactivated Vaccine Type and Application
Table 109. iBio, Inc. COVID-19 Inactivated Vaccine Major Business
Table 110. iBio, Inc. COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 111. iBio, Inc. SWOT Analysis
Table 112. iBio, Inc. COVID-19 Inactivated Vaccine Product and Solutions
Table 113. iBio, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 114. Sanofi Pasteur Corporate Information, Location and Competitors
Table 115. Sanofi Pasteur COVID-19 Inactivated Vaccine Major Business
Table 116. Sanofi Pasteur COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 117. Sanofi Pasteur SWOT Analysis
Table 118. Sanofi Pasteur COVID-19 Inactivated Vaccine Product and Solutions
Table 119. Sanofi Pasteur COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 120. GSK Corporate Information, Location and Competitors
Table 121. GSK COVID-19 Inactivated Vaccine Major Business
Table 122. GSK COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 123. GSK SWOT Analysis
Table 124. GSK COVID-19 Inactivated Vaccine Product and Solutions
Table 125. GSK COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 126. Curevac Corporate Information, Location and Competitors
Table 127. Curevac COVID-19 Inactivated Vaccine Major Business
Table 128. Curevac COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 129. Curevac SWOT Analysis
Table 130. Curevac COVID-19 Inactivated Vaccine Product and Solutions
Table 131. Curevac COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 132. ImmunoPrecise Corporate Information, Location and Competitors
Table 133. ImmunoPrecise COVID-19 Inactivated Vaccine Major Business
Table 134. ImmunoPrecise COVID-19 Inactivated Vaccine Total Revenue (USD Million) (2017-2018)
Table 135. ImmunoPrecise SWOT Analysis
Table 136. ImmunoPrecise COVID-19 Inactivated Vaccine Product and Solutions
Table 137. ImmunoPrecise COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 138. Global COVID-19 Inactivated Vaccine Revenue (Million USD) by Players (2015-2020)
Table 139. Global COVID-19 Inactivated Vaccine Revenue Share by Players (2015-2020)
Table 140. Global COVID-19 Inactivated Vaccine Revenue (Million USD) by Regions (2015-2020)
Table 141. Global COVID-19 Inactivated Vaccine Revenue Market Share by Regions (2015-2020)
Table 142. North America COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
Table 143. North America COVID-19 Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Table 144. Europe COVID-19 Inactivated Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 145. Asia-Pacific COVID-19 Inactivated Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 146. South America COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
Table 147. South America COVID-19 Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Table 148. Middle East and Africa COVID-19 Inactivated Vaccine Revenue (Million USD) by Countries (2015-2020)
Table 149. Middle East and Africa COVID-19 Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Table 150. Global COVID-19 Inactivated Vaccine Revenue (Million USD) by Type (2015-2020)
Table 151. Global COVID-19 Inactivated Vaccine Revenue Share by Type (2015-2020)
Table 152. Global COVID-19 Inactivated Vaccine Revenue Forecast by Type (2021-2025)
Table 153. Global COVID-19 Inactivated Vaccine Revenue by Application (2015-2020)
Table 154. Global COVID-19 Inactivated Vaccine Revenue Share by Application (2015-2020)
Table 155. Global COVID-19 Inactivated Vaccine Revenue Forecast by Application (2021-2025)
Table 156. Global COVID-19 Inactivated Vaccine Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. COVID-19 Inactivated Vaccine Picture
Figure 2. Global COVID-19 Inactivated Vaccine Revenue Market Share by Type in 2019
Figure 3. In Clinical Trials Picture
Figure 4. Out-of-Clinical Trials Picture
Figure 5. COVID-19 Inactivated Vaccine Revenue Market Share by Application in 2019
Figure 6. Hospital Picture
Figure 7. Clinic Picture
Figure 8. Other Picture
Figure 9. Global COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America COVID-19 Inactivated Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe COVID-19 Inactivated Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific COVID-19 Inactivated Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America COVID-19 Inactivated Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa COVID-19 Inactivated Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global COVID-19 Inactivated Vaccine Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global COVID-19 Inactivated Vaccine Revenue Share by Players in 2019
Figure 17. Global Top 5 Players COVID-19 Inactivated Vaccine Revenue Market Share in 2019
Figure 18. Global Top 10 Players COVID-19 Inactivated Vaccine Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global COVID-19 Inactivated Vaccine Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global COVID-19 Inactivated Vaccine Revenue Market Share by Regions (2015-2020)
Figure 22. Global COVID-19 Inactivated Vaccine Revenue Market Share by Regions in 2018
Figure 23. North America COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 24. Europe COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 26. South America COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 28. North America COVID-19 Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Figure 29. North America COVID-19 Inactivated Vaccine Revenue Market Share by Countries in 2019
Figure 30. USA COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 31. Canada COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 32. Mexico COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 33. Europe COVID-19 Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Figure 34. Europe COVID-19 Inactivated Vaccine Revenue Market Share by Countries in 2019
Figure 35. Germany COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 36. UK COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 37. France COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 38. Russia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 39. Italy COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific COVID-19 Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific COVID-19 Inactivated Vaccine Revenue Market Share by Countries in 2019
Figure 42. China COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 43. Japan COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 44. Korea COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 45. India COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 47. South America COVID-19 Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Figure 48. South America COVID-19 Inactivated Vaccine Revenue Market Share by Countries in 2019
Figure 49. Brazil COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 50. Argentina COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa COVID-19 Inactivated Vaccine Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa COVID-19 Inactivated Vaccine Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 54. UAE COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 55. Egypt COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 56. South Africa COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
Figure 57. Global COVID-19 Inactivated Vaccine Revenue Share by Type (2015-2020)
Figure 58. Global COVID-19 Inactivated Vaccine Revenue Share by Type in 2019
Figure 59. Global COVID-19 Inactivated Vaccine Market Share Forecast by Type (2021-2025)
Figure 60. Global In Clinical Trials Revenue Growth Rate (2015-2020)
Figure 61. Global Out-of-Clinical Trials Revenue Growth Rate (2015-2020)
Figure 62. Global COVID-19 Inactivated Vaccine Revenue Share by Application (2015-2020)
Figure 63. Global COVID-19 Inactivated Vaccine Revenue Share by Application in 2019
Figure 64. Global COVID-19 Inactivated Vaccine Market Share Forecast by Application (2021-2025)
Figure 65. Global Hospital Revenue Growth Rate (2015-2020)
Figure 66. Global Clinic Revenue Growth Rate (2015-2020)
Figure 67. Global Other Revenue Growth Rate (2015-2020)
Figure 68. Global COVID-19 Inactivated Vaccine Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global COVID-19 Inactivated Vaccine Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global COVID-19 Inactivated Vaccine Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
Figure 72. Europe COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
Figure 74. South America COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
エボラワクチンの世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Ebola Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…- 新型コロナウイルス感染症RNAワクチンの世界市場2020年：企業別、地域別、種類・用途別 Market Overview The COVID-19 RNA Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- 新型コロナウイルス感染症DNAワクチンの世界市場2020年：企業別、地域別、種類・用途別 Market Overview The COVID-19 DNA Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- 新型コロナウイルス感染症組換えタンパク質ワクチンの世界市場2020年：企業別、地域別、種類・用途別 Market Overview The COVID-19 Recombinant Protein Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chai…
- アデノウイルスベクターワクチンの世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Adenovirus Vector Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…